Welcome to the Lilly Scientific Information Page for DDW 2026
Digestive Disease Week® (DDW)
Chicago, Illinois
Quicklinks
See how Lilly supports external requests for provision of study drug and/or financial support
To stay informed on the latest science and innovation, please be sure to follow us on Twitter/X
To stay informed on the latest science and innovation from Lilly Medical, please be sure to follow us on LinkedIn
Disclosures
SATURDAY
SATURDAY
- Disease State: Ulcerative Colitis
- Presented by: Boyd Steere
- Molecule(s): Mirikizumab
Mirikizumab Induction Response is Associated with Molecular- and Cellular-Based Tissue Archetype Features of Mucosal Recovery in Ulcerative Colitis
Trial(s) Overview:
SATURDAY
SATURDAY
SATURDAY
- Disease State: Ulcerative Colitis
- Presented by: Boyd Steere
- Molecule(s): Mirikizumab
A Panel of 11 Genes From Colon And Rectum Biopsies in the LUCENT-URGE Study Shows Utility for Predicting Responses to Mirikizumab Treatment of Ulcerative Colitis
Trial(s) Overview:
SATURDAY
SATURDAY
- Disease State: Ulcerative Colitis
- Presented by: David T. Rubin
- Molecule(s): Mirikizumab
Mirikizumab Provides Positive Histologic and Endoscopic Outcomes in Patients with Moderately to Severely Active Ulcerative Colitis
Trial(s) Overview:
MONDAY
- Disease State: Crohn's Disease
- Presented by: Bruce E. Sands
- Molecule(s): Mirikizumab
Mirikizumab Demonstrated Sustained and Durable Long-Term Efficacy and Favorable Safety in Week 52 Endoscopic Responders with Crohn's Disease: 3-Year VIVID-2 Open-Label Extension Interim Results
Trial(s) Overview:
SATURDAY
SATURDAY
MONDAY
To receive the latest science and innovation from LillyMedical, be sure to follow us via our Twitter handle @LillyMedical. See our community guidelines.
Contact Us
Call us
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)